other material
confidence high
sentiment positive
materiality 0.75
Korro Bio selects KRRO-111 for AATD; pre-clinical results show >90% RNA editing
Korro Bio, Inc.
- KRRO-111 is a GalNAc-conjugated oligonucleotide delivered subcutaneously for AATD.
- In vivo editing >90% of SERPINA1 transcript, translating to ~90% repaired functional AAT protein in mouse model.
- Repeated dosing nearly eliminated active Z-protein production; pre-existing aggregates progressively cleared.
- Company plans to present additional KRRO-111 data at future scientific meeting.
- CEO noted well-capitalized position to advance both KRRO-111 and KRRO-121 toward clinical data.